As flu season emerges, BD completes syringe manufacturing lines with help from US government; Hot off summertime debut on NYSE, construction on Stevanato's midwest site begins
BD has upped the US government’s access to safety injection devices through the investment of two new syringe and needle manufacturing lines.
The company completed construction of the lines on a sped-up timeline through a partnership with the US Department of Health and Human Services. BARDA invested $42 million into the roughly $70 million project to add lines in Holdrege, NE.
“As the fight against COVID-19 continues, we are steadfast in our commitment to securing the nation’s supply continuity of these critical injection devices,” BD president of medication delivery solutions Rick Byrd, said in a press release. “Our teams are working tirelessly – as they have been since the beginning of the pandemic – to ensure that all of our customers, including the U.S. government, have the supplies they need to vaccinate against this virus while simultaneously managing routine, preventative health care needs, such as the seasonal flu.”
The move highlights a shift toward domestic manufacturing, to ensure ample supply as the US heads into flu vaccination season.
Construction on Stevanato’s midwest site begins
An Italian manufacturer broke ground on a $145 million facility in Fisher, IN last week in a move set to bring its operations closer to US customers.
The 370,000 square-foot building is set to become operational in 2023, and have production lines equipped with Stevanato’s EZ-Fill technology. That tech helps reduce the drug’s time to market, lowers the cost of ownership and reduces supply chain risk.
The new site will also be a home for after-sales support.
“We are thrilled to begin construction on our new U.S. hub, and expand our presence in one of the fastest growing markets where we see increasing demand. We believe this will allow us to further enhance our services to our valued North America customers and underscores our desire to ensure supply chain security, just in time delivery and reliable sourcing in terms of surge capacity,” CEO Franco Moro said in a press release. “We are proud to join the Fishers community. This is an exciting achievement for our company, and we look forward to continuing to enable our customers – in the U.S. and around the world – to deliver safe and effective treatments to patients.”
In July, the company debuted on the New York Stock Exchange with a valuation of $5 billion.
LSNE doubles capacity
As the demand for freeze drying grows, LSNE has doubled the capacity for it at its Wisconsin plant, the company announced Monday.
The Bedford, NH-based CDMO has upped its high-speed fill line to bring another 120 square feet to its commercial lyophilizer, which is equipped with systems meant to best protect high value active pharmaceutical ingredients.
“In response to our clients’ needs, we have expanded our lyophilization capacity. There continues to be an uptick in their demand for lyophilization and we accelerated our plans to add capacity to be ready this month,” site head Doug Craig said.